Zenas BioPharma, Inc.
ZBIO
$19.16
-$1.24-6.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -- | -- |
| Cost of Revenue | -24.85% | 2.60% | 27.27% | 54.18% | -540.70% |
| Gross Profit | 18.28% | -2.60% | -27.27% | -10.02% | 565.19% |
| SG&A Expenses | 35.98% | 76.79% | 105.87% | 151.67% | 162.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.63% | 16.09% | 38.94% | 71.62% | 144.65% |
| Operating Income | -28.21% | -16.09% | -38.94% | -35.36% | -124.48% |
| Income Before Tax | -360.63% | -33.40% | -37.46% | -21.50% | -114.84% |
| Income Tax Expenses | -75.29% | -- | -- | -- | 42.52% |
| Earnings from Continuing Operations | -357.08% | -33.40% | -37.51% | -20.77% | -113.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -357.08% | -33.40% | -37.51% | -20.77% | -113.95% |
| EBIT | -28.21% | -16.09% | -38.94% | -35.36% | -124.48% |
| EBITDA | -28.26% | -16.17% | -39.03% | -35.44% | -124.62% |
| EPS Basic | -261.63% | 75.64% | 94.85% | 95.51% | 92.13% |
| Normalized Basic EPS | -11.70% | 78.01% | 94.85% | 95.48% | 92.00% |
| EPS Diluted | -261.63% | 75.64% | 94.85% | 95.51% | 92.13% |
| Normalized Diluted EPS | -11.70% | 78.01% | 94.85% | 95.48% | 92.00% |
| Average Basic Shares Outstanding | 26.39% | 447.69% | 2,571.18% | 2,589.71% | 2,620.21% |
| Average Diluted Shares Outstanding | 26.39% | 447.69% | 2,571.18% | 2,589.71% | 2,620.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |